Express Scripts (NASDAQ:ESRX)‘s stock had its “sell” rating reissued by Raymond James Financial in a research report issued to clients and investors on Friday.

Several other research firms have also recently weighed in on ESRX. SunTrust Banks set a $82.00 price target on shares of Express Scripts and gave the stock a “buy” rating in a report on Thursday. Robert W. Baird raised shares of Express Scripts from a “neutral” rating to an “outperform” rating and upped their price target for the stock from $72.00 to $81.00 in a report on Friday. BidaskClub raised shares of Express Scripts from a “hold” rating to a “buy” rating in a report on Thursday. Maxim Group upped their price target on shares of Express Scripts from $78.00 to $87.00 and gave the stock a “buy” rating in a report on Thursday. Finally, ValuEngine raised shares of Express Scripts from a “hold” rating to a “buy” rating in a report on Monday, December 4th. Five research analysts have rated the stock with a sell rating, ten have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $74.40.

Shares of Express Scripts (ESRX) opened at $71.55 on Friday. The company has a current ratio of 0.73, a quick ratio of 0.61 and a debt-to-equity ratio of 0.86. Express Scripts has a 1-year low of $55.80 and a 1-year high of $73.42. The stock has a market cap of $40,523.99, a price-to-earnings ratio of 10.46, a price-to-earnings-growth ratio of 1.06 and a beta of 0.88.

Express Scripts (NASDAQ:ESRX) last issued its earnings results on Tuesday, October 24th. The company reported $1.90 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.90. The business had revenue of $24.68 billion for the quarter, compared to analysts’ expectations of $25.68 billion. Express Scripts had a net margin of 3.64% and a return on equity of 25.46%. The business’s revenue for the quarter was down 2.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.74 EPS. equities research analysts forecast that Express Scripts will post 7.02 earnings per share for the current fiscal year.

In other Express Scripts news, CEO Timothy C. Wentworth purchased 8,000 shares of the business’s stock in a transaction on Tuesday, October 31st. The stock was acquired at an average cost of $61.13 per share, for a total transaction of $489,040.00. Following the completion of the transaction, the chief executive officer now directly owns 98,628 shares in the company, valued at approximately $6,029,129.64. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Phyllis S. Anderson sold 643 shares of the company’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $62.37, for a total transaction of $40,103.91. The disclosure for this sale can be found here. 0.68% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Nordea Investment Management AB boosted its position in Express Scripts by 1.4% during the second quarter. Nordea Investment Management AB now owns 7,116,445 shares of the company’s stock valued at $454,314,000 after buying an additional 97,953 shares during the period. Van ECK Associates Corp boosted its position in Express Scripts by 5.1% during the third quarter. Van ECK Associates Corp now owns 506,511 shares of the company’s stock valued at $32,072,000 after buying an additional 24,728 shares during the period. First Trust Advisors LP boosted its position in Express Scripts by 25.3% during the second quarter. First Trust Advisors LP now owns 708,955 shares of the company’s stock valued at $45,260,000 after buying an additional 143,163 shares during the period. Lazard Asset Management LLC boosted its position in Express Scripts by 81.8% during the second quarter. Lazard Asset Management LLC now owns 112,666 shares of the company’s stock valued at $7,192,000 after buying an additional 50,707 shares during the period. Finally, Victory Capital Management Inc. boosted its position in Express Scripts by 12.5% during the third quarter. Victory Capital Management Inc. now owns 35,421 shares of the company’s stock valued at $2,243,000 after buying an additional 3,940 shares during the period. Institutional investors and hedge funds own 88.44% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Express Scripts (ESRX) Stock Rating Reaffirmed by Raymond James Financial” was reported by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this report can be accessed at https://www.watchlistnews.com/express-scripts-esrx-stock-rating-reaffirmed-by-raymond-james-financial/1769301.html.

Express Scripts Company Profile

Express Scripts, Inc is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM).

Analyst Recommendations for Express Scripts (NASDAQ:ESRX)

Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.